DCC 3014

Drug Profile

DCC 3014

Alternative Names: DCC3014

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 16 Feb 2017 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03069469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top